US: AOLS - Aeolus Pharmaceuticl

Rentabilidade por seis meses: +200%

Cronograma de promoção Aeolus Pharmaceuticl


Sobre a empresa

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology.

mais detalhes
Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

IPO date 1996-02-01
ISIN US00765G1094
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.aeoluspharma.com
Цена ао 0.0001
Alteração de preço por dia: 0% (0.0003)
Alteração de preço por semana: 0% (0.0003)
Alteração de preço por mês: +200% (0.0001)
Alteração de preço em 3 meses: +200% (0.0001)
Mudança de preço em seis meses: +200% (0.0001)
Mudança de preço por ano: +200% (0.0001)
Mudança de preço em 3 anos: -62.5% (0.0008)
Mudança de preço em 5 anos: -76.92% (0.0013)
Mudança de preço em 10 anos: 0% (0.0003)
Mudança de preço desde o início do ano: 0% (0.0003)

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Eficiência

Nome Significado Nota
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA 0 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -71.53 0
Rentabilidade Ebitda, % -49.12 0
Rentabilidade EPS, % -67.11 0
Total: 2

Supervisor Cargo Pagamento Ano de nascimento
Mr. John L. Mcmanus Chief Executive Officer and President 1964 (61 ano)
Mr. Christopher Stanley Vice President of Operations

Endereço: United States, Mission Viejo, 26361 Crown Valley Parkway - abrir no Google Maps, abrir mapas Yandex
Site: https://www.aeoluspharma.com